Olympian Clinical Research

1. Incyte Corporation $2,999,659 1,626 payments
2. Pfizer Inc. $419,183 149 payments
3. Amgen Inc. $348,989 6 payments
4. Novartis Pharmaceuticals Corporation $237,729 33 payments
5. Ucb SA $172,061 28 payments
6. LEO Pharma AS $121,096 50 payments
7. Endo Pharmaceuticals Inc. $81,315 22 payments
8. Avanir Pharmaceuticals, Inc. $72,697 19 payments
9. Neurocrine Biosciences, Inc. $31,852 25 payments
10. E.R. Squibb & Sons, L.L.C. $22,136 2 payments

1. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa $673,327 45 payments
2. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $515,384 549 payments
3. Interchangeability Study - ABP 654 $259,180 3 payments
4. A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma $247,914 15 payments
5. TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $192,329 37 payments
6. TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $179,624 25 payments
7. A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo $178,278 46 payments
8. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo $167,731 34 payments
9. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $141,274 184 payments
10. An Openlabel Extension Study to Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis $138,265 34 payments

1. Other $2,992 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.